96 related articles for article (PubMed ID: 6135865)
1. Steroids and complement activation in rheumatoid arthritis.
Brandslund I; Peters ND; Ejstrup L; Teisner B; Rasmussen GG
Lancet; 1983 Aug; 2(8345):346-7. PubMed ID: 6135865
[No Abstract] [Full Text] [Related]
2. Development and clinical application of electroimmunoassays for the direct quantification of the complement C3 split products C3c and C3d.
Brandslund I; Teisner B; Hyltoft Petersen P; Svehag SE
Scand J Clin Lab Invest Suppl; 1984; 168():57-73. PubMed ID: 6333715
[TBL] [Abstract][Full Text] [Related]
3. Steroids reduce complement activation in rheumatoid arthritis.
Brandslund I; Peters ND; Ejstrup L
Int J Tissue React; 1985; 7(2):161-5. PubMed ID: 3875589
[TBL] [Abstract][Full Text] [Related]
4. Complement C3c and C3d in plasma and synovial fluid in rheumatoid arthritis.
Berkowicz A; Kappelgaard E; Petersen J; Nielsen H; Ingemann-Hansen T; Halkjaer-Kristensen J; Sørensen H
Acta Pathol Microbiol Immunol Scand C; 1983 Dec; 91(6):397-402. PubMed ID: 6608857
[TBL] [Abstract][Full Text] [Related]
5. Monoclonal antibodies against complement 3 neoantigens for detection of immune complexes and complement activation. Relationship between immune complex levels, state of C3, and numbers of receptors for C3b.
Aguado MT; Lambris JD; Tsokos GC; Burger R; Bitter-Suermann D; Tamerius JD; Dixon FJ; Theofilopoulos AN
J Clin Invest; 1985 Oct; 76(4):1418-26. PubMed ID: 2932466
[TBL] [Abstract][Full Text] [Related]
6. Reduction of complement activation in rheumatoid arthritis by steroid treatment.
Ernst E; Espersen GT; Andersen MV
Int J Tissue React; 1990; 12(2):77-9. PubMed ID: 2170287
[TBL] [Abstract][Full Text] [Related]
7. The use of C3d as a means of monitoring clinical activity in systemic lupus erythematosus and rheumatoid arthritis.
Morrow WJ; Williams DJ; Ferec C; Casburn-Budd R; Isenberg DA; Paice E; Snaith ML; Youinou P; Le Goff P
Ann Rheum Dis; 1983 Dec; 42(6):668-71. PubMed ID: 6606402
[TBL] [Abstract][Full Text] [Related]
8. Complement activation during cardiopulmonary bypass by heparin-protamine interaction.
Best N; Sinosich MJ; Teisner B; Grudzinskas JG; Fisher MM
Br J Anaesth; 1984 Apr; 56(4):339-43. PubMed ID: 6608952
[TBL] [Abstract][Full Text] [Related]
9. Classical pathway activation during an adverse response to protamine sulphate.
Best N; Teisner B; Grudzinskas JG; Fisher MM
Br J Anaesth; 1983 Nov; 55(11):1149-53. PubMed ID: 6605758
[TBL] [Abstract][Full Text] [Related]
10. Changes in PMN leukocyte migration activity and complement C3d levels in RA patients with high disease activity during steroid treatment.
Espersen GT; Ernst E; Vestergaard M; Pedersen JO; Grunnet N
Scand J Rheumatol; 1989; 18(1):51-6. PubMed ID: 2784866
[TBL] [Abstract][Full Text] [Related]
11. Reflection of disease activity in rheumatoid arthritis by indices of activation of the classical complement pathway.
Makinde VA; Senaldi G; Jawad AS; Berry H; Vergani D
Ann Rheum Dis; 1989 Apr; 48(4):302-6. PubMed ID: 2785367
[TBL] [Abstract][Full Text] [Related]
12. Activation of classical pathway complement in chronic inflammation. Elevated levels of circulating C3d and C4d split products in rheumatoid arthritis and Crohn's disease.
Petersen NE; Elmgreen J; Teisner B; Svehag SE
Acta Med Scand; 1988; 223(6):557-60. PubMed ID: 3389208
[TBL] [Abstract][Full Text] [Related]
13. C3d as a marker of extra-articular features in rheumatoid arthritis.
Peretz A; Aoun M; Duchateau J; Famaey JP
Scand J Rheumatol; 1986; 15(4):407-9. PubMed ID: 3493525
[No Abstract] [Full Text] [Related]
14. Clinical application of a new nephelometric technique to measure complement activation.
Vergani D; Bevis L; Nasaruddin BA; Mieli-Vergani G; Tee DE
J Clin Pathol; 1983 Jul; 36(7):793-7. PubMed ID: 6602812
[TBL] [Abstract][Full Text] [Related]
15. Circulating C3, C4, and C3 split products (C3c and C3d) during normal pregnancy.
Teisner B; Hau J; Tucker M; Lahood J; Grudzinskas JG
Am J Reprod Immunol (1980); 1982 Dec; 2(6):309-11. PubMed ID: 6984294
[TBL] [Abstract][Full Text] [Related]
16. Complement activation during normal pregnancy.
Teisner B; Grudzinskas JG
Placenta Suppl; 1982; 4():119-24. PubMed ID: 6985440
[No Abstract] [Full Text] [Related]
17. Direct quantitation of activated C3 in human plasma with monoclonal anti-iC3b-C3d-neoantigen.
Kanayama Y; Kurata Y; McMillan R; Tamerius JD; Negoro N; Curd JG
J Immunol Methods; 1986 Apr; 88(1):33-6. PubMed ID: 2420896
[TBL] [Abstract][Full Text] [Related]
18. Association of rheumatoid factor with complement activation in rheumatoid arthritis and other diseases.
Reyes PA; Maluf JG; Curd JG; Vaughan JH
Clin Exp Immunol; 1983 Aug; 53(2):391-6. PubMed ID: 6883809
[TBL] [Abstract][Full Text] [Related]
19. Measurement of C3 conversion by ELISA estimation of neo-determinants on the C3d moiety.
Holmskov-Nielsen U; Jensenius JC; Teisner B; Erb K
J Immunol Methods; 1986 Nov; 94(1-2):1-6. PubMed ID: 2431062
[TBL] [Abstract][Full Text] [Related]
20. Cleavage of the complement system C3 component by HIV-1 proteinase.
Kisselev AF; Mentele R; von der Helm K
Biol Chem; 1997 May; 378(5):439-42. PubMed ID: 9191031
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
